Common Stock, par value $0.0001 per share
- Symbol
- MGRX
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Mangoceuticals, Inc.
MGRXNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. As previously disclosed, on February 4, 2026, Mangoceuticals, Inc. (the “Company”) received a deficiency notification letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price of the Company’s common stock had closed below $1…
Recent company filings
- Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security HoldersNov 13, 2026
- 1-A filingNov 12, 2026
- Submission of Matters to a Vote of Security Holders · Shareholder Director Nominations · Other EventsNov 6, 2026
- PRE 14A filingNov 6, 2026
- Entry into a Material Definitive AgreementOct 9, 2026
Registered securities in this filing
MANGOCEUTICALS, INC. · 8-K · Filed 2026-08-04
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item
8.01 Other Events.
As
previously disclosed, on February 4, 2026, Mangoceuticals, Inc. (the “Company”) received a deficiency notification letter
from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that
the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price of the Company’s common stock had closed
below $1.00 per share for the previous 30 consecutive business days.
In
accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial compliance period of 180 calendar days, or until
August 3, 2026, to regain compliance with the minimum bid price requirement (the “Bid Price Requirement”).
On
August 4, 2026, the Company received a letter (the “Second Notice”) from Nasdaq advising that the Staff has determined that
the Company is eligible for an additional 180 calendar day compliance period, or until February 1, 2027 (the “Second Compliance
Period”), to regain compliance. According to the Second Notice, the Staff’s determination was based on (i) the Company meeting
the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing
on The Nasdaq Capital Market, with the exception of the Bid Price Requirement, and (ii) the Company’s written notice of its intention
to cure the deficiency during the Second Compliance Period by effecting a reverse stock split, if necessary.
The
Second Notice has no effect on the listing or trading of the Company’s common stock at this time. The Company intends to actively
monitor the closing bid price of its common stock and will take all necessary actions to resolve this listing deficiency.
On
August 4, 2026, the Company issued a press release announcing the receipt of the Second Notice and commenting on the Company’s
recently announced entrance into a business combination agreement with Nuclea Energy Inc. A copy of the press release is filed as Exhibit
99.1 to this Form 8-K and is incorporated herein by reference.
Filed exhibits (1)
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination Dallas, Texas - August 4, 2026 - Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) today announced it has received an additional 180-calendar-day extension from the Nasdaq Stock Market (“Nasdaq”) to regain compliance with the minimum bid price requirement, as outlined in Nasdaq Listing Rule 5550(a)(2).The Company now has until February 1, 2027 to meet the requirement for its shares of common stock to maintain a closing bid price of at least US $1.00 per share for a minimum of 10 consecutive business days. Nasdaq granted the extension after determining that Mangoceuticals meets the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, and following Mangoceuticals providing written notice of its intention to cure the deficiency within the extension period, if necessary, through a reverse stock split. This news comes as the Company continues to advance its …
Open exhibit ↗